Bristol-Myers Squibb Company financials
Key figures from Bristol-Myers Squibb Company's filings with the U.S. Securities and Exchange Commission: the latest quarter against a year earlier, and the trend across recent quarters and fiscal years.
Latest quarter vs a year earlier
| Metric | Sep 2026 | Sep 2025 | Change |
|---|---|---|---|
| Revenue | $13.1B | $12.2B | +6.9% |
| Net income | $2.2B | $2.2B | -1.8% |
| Free cash flow | $3.8B | $6.0B | -36.0% |
| Gross margin | 68.3% | 71.9% | -3.6 pts |
| Operating margin | — | — | — |
| Net margin | 16.5% | 18.0% | -1.5 pts |
Quarterly trend
Fiscal years
| Fiscal year | Revenue | Net income | Net margin | Free cash flow | EPS (diluted) |
|---|---|---|---|---|---|
| FY Dec 2025 | $48.2B | $7.1B | 14.6% | $12.8B | $3.46 |
| FY Dec 2024 | $48.3B | -$8.9B | -18.5% | $13.9B | -$4.41 |
| FY Dec 2023 | $45.0B | $8.0B | 17.8% | $12.7B | $3.86 |
| FY Dec 2022 | $46.2B | $6.3B | 13.7% | $11.9B | $2.95 |
| FY Dec 2021 | $46.4B | $7.0B | 15.1% | $15.2B | $3.12 |
* Fiscal fourth quarter computed from the annual filing minus the three reported quarters. All figures from company filings with the SEC.